Skip to main content

CORRECTION article

Front. Immunol., 14 September 2023
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1290431

Corrigendum: Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine

This article is a correction to:

  1. Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine

    1. Read original article
Marina Barrio-CalvoMarina Barrio-CalvoSren Vester KofoedSøren Vester KofoedSofie Cens HolsteSofie Cens HolsteAnders Bundgrd SrensenAnders Bundgård SørensenNadia ViborgNadia ViborgJens Vindahl KringelumJens Vindahl KringelumDaniela Kleine-KohlbrecherDaniela Kleine-KohlbrecherChristian Skjdt SteenmansChristian Skjødt SteenmansChristian Bahne ThygesenChristian Bahne ThygesenBirgitte RnBirgitte RønøStine Friis*Stine Friis*
  • Evaxion Biotech, Hørsholm, Denmark

A Corrigendum on
Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine

by Barrio-Calvo M, Kofoed SV, Holste SC, Sørensen AB, Viborg N, Kringelum JV, Kleine-Kohlbrecher D, Steenmans CS, Thygesen CB, Rønø B and Friis S (2023) Front. Immunol. 14:1234912. doi: 10.3389/fimmu.2023.1234912

In the published article, there was an error in the Funding statement. The authors inadvertently omitted a funding disclosure that should have been included in the funding section of the manuscript. The correct Funding statement appears below.

Funding

The Innovation Fund Denmark partially funded MB-C (1044-00028B) and NV (5189-00187B). The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: APC-targeting, CCL19, neoantigens, DNA vaccine, cancer immunotherapy

Citation: Barrio-Calvo M, Kofoed SV, Holste SC, Sørensen AB, Viborg N, Kringelum JV, Kleine-Kohlbrecher D, Steenmans CS, Thygesen CB, Rønø B and Friis S (2023) Corrigendum: Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine. Front. Immunol. 14:1290431. doi: 10.3389/fimmu.2023.1290431

Received: 07 September 2023; Accepted: 08 September 2023;
Published: 14 September 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Barrio-Calvo, Kofoed, Holste, Sørensen, Viborg, Kringelum, Kleine-Kohlbrecher, Steenmans, Thygesen, Rønø and Friis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Stine Friis, sf@evaxion-biotech.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.